arrow
C

Christina Kunz

Boehringer Ingelheim Pharma GmbH & Co. KG
H指数:31
被引数:3,190

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age (vol 35, pg 809, 2021)
LEUKEMIA
IF13.4
2021-11-160
OAAI
Neonatal antibiotic exposure impairs child growth during the first six years of life by perturbing intestinal microbial colonization
2021-01-26127
OAAI
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
2021-01-0714
OAAI
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
LEUKEMIA
IF13.4
2020-07-2010
OAAI
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
LEUKEMIA
IF13.4
2020-02-0734
PREAI
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
2019-05-2829
OAAI
CCR5 inhibition: macrophage repolarization therapy for colorectal cancer
2017-07-010
PRE
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
2016-08-1811
OAAI
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

德语骨髓瘤多中心组 (GMMG) 试验复发的基本原理和设计: 一项随机,开放,多中心III期试验,比较来那度胺/地塞米松与来那度胺/地塞米松联合后续自体干细胞移植和来那度胺维持治疗复发性多发性骨髓瘤

2016-04-257
OAAI